The unlikely legalization of medical cannabis in Albania: a case study
Medical ethics, cannabis, legalization, THC (tetra-hydro-cannabinol), policymaking
Cannabis abuse has been an issue of major concern for the Albanian society in recent years, following the wide illegal planting of the species. Legal lacunas, weaknesses from the drug-controlling agencies, and the easiness of harvesting Cannabis sativa plants have contributed to the creation of a general negative opinion toward a potential use of its active principles for medical purposes. Professionals of the field and policymakers are largely focused on harm reduction activities, thus bypassing the option of legalizing cannabinoids for clinical conditions that might find relief in their use.The discussion of a case suffering from postherpetic neuralgia shows how this negative opinion is depriving Albanian patients from an otherwise helpful pharmacological option whose efficacy has been confirmed by an important bulk of research. Uncovering the roots of this misperception will help address the issue. Clinicians with expertise need to have their say in the debate, since for the majority of countries where medicinal cannabis is legalized, this was due to consumer-led initiatives. Ensuring patients’ freedom as implied within the principle of autonomy is also a sound ethical support of such legalization.
Bruci Z, Papoutsis I, Athanaselis S, et al. First systematic evaluation of the potency of Cannabis sativa plants grown in Albania. Forensic Sci Int. 2012; 10; 222(1-3):40-6.
Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol. 2005; 146(7): 913-5.
Hughes B, Wiessing L, Des Jarlais D, Griffiths P. Could cannabis liberalisation lead to wider changes in drug policies and outcomes? Int J Drug Policy. 2018; 51:156-59.
Matua L, Muharremi G, Petrela E, Koçibelli M, Vyshka G, Xhemali B. The use of psychoactive substances and illegal drugs in the Albanian society. Curr Drug Res Rev. 2019; 11(1):73-9.
Blumenson E, Nilsen E. Liberty lost: the moral case for marijuana law reform. Indiana Law Journal. 2010; 85(1): 279.
Pfeifer DJ. Smoking gun: the moral and legal struggle for medical marijuana. Touro Law Review. 2011; 27:339-78.
Clark PA, Capuzzi K, Fick C. Medical marijuana: medical necessity versus political agenda. Med Sci Monit. 2011; 17(12): RA249-RA261.
Candela García E, Espada Sánchez JP. Una revisión histórica sobre los usos del cannabis y su regulación. Salud y drogas. 2006; 6(1): 47-40.
Mechoulam R, Gaoni Y. A total synthesis of DL-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc. 1965; 87: 3273-5.
Lötsch J, Weyer-Menkhoff I, Tegeder I. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. Eur J Pain. 2018; 22(3):471-84.
Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 2019; 9(2):191-203.
Newton-Howes G, McBride S. Medicinal cannabis: moving the debate forward. N Z Med J. 2016; 129(1445):103-9.
Hayry M. Prescribing cannabis: freedom, autonomy, and values. J Med Ethics. 2004; 30(4): 333-6.
Helgesson G, Lynøe N, Juth N. Value-impregnated factual claims and slippery-slope arguments. Med Health Care Philos. 2017; 20(1):147-50.
De Hoop B, Heerdink ER, Hazekamp A. Medicinal Cannabis on Prescription in the Netherlands: Statistics for 2003-2016. Cannabis Cannabinoid Res. 2018; 3(1): 54-55.
Reis-Pina P. The prescription of medicinal cannabis and the virtue of prudence: without phobia(s) nor philia(s). Acta Med Port. 2019; 32(4): 323-24.